Skip to content
GENB·Nasdaq·US

Generate Biomedicines

Generate Biomedicines is a biotechnology company focused on using AI and machine learning to design and develop new therapeutic proteins and drug candidates. It operates a platform-based drug discovery model and collaborates with pharmaceutical partners, including Amgen.

Recent Activity

Updated Oct 17, 2026
–Generate Biomedicines and Zealand Pharma entered a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases.
–The collaboration combines Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates.

Past updates are part of the Pro plan.

Thematic Position

GENB

Relationship Groups

Partners2
Competitors1

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

3 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

state aid/price controltariffdrug pricing regulation
Executive Order 14297 establishes most-favored-nation drug price targets
SEC 10-QMay 7, 2026

The full regulatory passage is part of the Pro plan.

19 more · Regulatory and geopolitical insights are part of the Pro plan.